2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.38 Durable Response to Savolitinib in Advanced EGFR-WT NSCLC with MET Amplification: Case Series

Pdf Summary

In a case series examining the effects of Savolitinib on advanced non-small cell lung cancer (NSCLC) with MET amplification, promising results were observed. Savolitinib, a highly selective MET tyrosine kinase inhibitor, has already been approved in China for treating advanced NSCLC with MET 14 exon skipping mutation after chemotherapy failure. This study aimed to evaluate its efficacy and safety when used as a first-line or salvage treatment in NSCLC patients with MET amplification but without EGFR, ALK, or ROS1 mutations.<br /><br />The study consisted of four patients with stage IVb EGFR wild-type NSCLC identified with MET amplification. Two of them started Savolitinib as first-line therapy, while the others received it post failure of previous treatments, including entrectinib, nab-paclitaxel, and carboplatin.<br /><br />Remarkably, all patients achieved a partial response (PR) within a month of starting Savolitinib, with three maintaining PR until the data cutoff and one experiencing disease progression after seven months. Molecular analysis identified various concurrent mutations and alterations like TP53, ARID1A, and others in patients, though these did not hinder the efficacy of Savolitinib.<br /><br />Regarding safety, three patients tolerated the treatment well with no adverse events, while one developed interstitial pneumonia, managed with steroids.<br /><br />The findings suggest Savolitinib induces a rapid and durable response in NSCLC patients with MET amplification, irrespective of treatment line and presence of other mutations. While the safety profile shows acceptable tolerability, confirming these results in larger cohorts with extended follow-ups is required. This study underscores the potential of Savolitinib as an effective treatment option for MET-amplified NSCLC.

Asset Subtitle

Jianwei Liu

Meta Tag

Speaker Jianwei Liu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Savolitinib

non-small cell lung cancer

NSCLC

MET amplification

tyrosine kinase inhibitor

EGFR wild-type

partial response

interstitial pneumonia

treatment efficacy

safety profile